Cargando…

Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction

LCZ696 (sacubitril/valsartan) can lower the risk of cardiovascular events in chronic heart failure. However, it is unclear whether LCZ696 can improve prognosis in patients with acute myocardial infarction (MI). The present study shows that LCZ696 can prevent cardiac rupture after MI, probably due to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishii, Masanobu, Kaikita, Koichi, Sato, Koji, Sueta, Daisuke, Fujisue, Koichiro, Arima, Yuichiro, Oimatsu, Yu, Mitsuse, Tatsuro, Onoue, Yoshiro, Araki, Satoshi, Yamamuro, Megumi, Nakamura, Taishi, Izumiya, Yasuhiro, Yamamoto, Eiichiro, Kojima, Sunao, Kim-Mitsuyama, Shokei, Ogawa, Hisao, Tsujita, Kenichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	PRECLINICAL RESEARCH
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059351/ https://www.ncbi.nlm.nih.gov/pubmed/30062181 http://dx.doi.org/10.1016/j.jacbts.2017.08.001

Ejemplares similares

The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
por: Jhund, Pardeep S., et al.
Publicado: (2015)

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization
por: Langenickel, Thomas H., et al.
Publicado: (2016)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction
por: Kobalava, Zhanna, et al.
Publicado: (2016)

Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension
por: Hsiao, H‐L, et al.
Publicado: (2017)

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens
por: Senni, Michele, et al.
Publicado: (2016)

Total Thrombus‐formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Oimatsu, Yu, et al.
Publicado: (2017)

Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual‐acting angiotensin receptor‐neprilysin inhibitor
por: Ushijima, Kentaro, et al.
Publicado: (2017)

Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation — The ATTRACTIVE-TTAS study
por: Ishii, Masanobu, et al.
Publicado: (2019)

Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice
por: Nakanishi, Nobuhiro, et al.
Publicado: (2020)

Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice
por: Nakanishi, Nobuhiro, et al.
Publicado: (2020)

Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3-induced pyroptosis via the TAK1/JNK signaling pathway
por: Shen, Jianfen, et al.
Publicado: (2021)

LCZ696 ameliorates lipopolysaccharide-induced endothelial injury
por: Gao, Aihong, et al.
Publicado: (2021)

Sacubitril/valsartan (LCZ696) ameliorates hyperthyroid-induced cardiac hypertrophy in male rats through modulation of miR-377, let-7 b, autophagy, and fibrotic signaling pathways
por: Khamis, Tarek, et al.
Publicado: (2022)

Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats
por: Alqahtani, Faleh, et al.
Publicado: (2020)

Total Thrombus-Formation Analysis System can Predict 1-Year Bleeding Events in Patients with Coronary Artery Disease
por: Mitsuse, Tatsuro, et al.
Publicado: (2020)

Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System
por: Ishii, Masanobu, et al.
Publicado: (2017)

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
por: Li, Bo, et al.
Publicado: (2017)

LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats
por: Miyoshi, Toru, et al.
Publicado: (2022)

A Destabilized Case of Stable Effort Angina Pectoris Induced by Low-dose Adenosine Triphosphate
por: Sueta, Daisuke, et al.
Publicado: (2016)

A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension
por: Zheng, Li, et al.
Publicado: (2021)

Total Thrombus‐Formation Analysis System (T‐TAS) Can Predict Periprocedural Bleeding Events in Patients Undergoing Catheter Ablation for Atrial Fibrillation
por: Ito, Miwa, et al.
Publicado: (2016)

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
por: McMurray, John, et al.
Publicado: (2015)

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?
por: Kaplinsky, Edgardo
Publicado: (2015)

Helicobacter pylori Seropositivity in Patients with Interleukin-1 Polymorphisms Is Significantly Associated with ST-Segment Elevation Myocardial Infarction
por: Tabata, Noriaki, et al.
Publicado: (2016)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

Effect and safety of LCZ696 in the treatment of hypertension: A meta-analysis of 9 RCT studies
por: Li, Qiongqiong, et al.
Publicado: (2019)

The protective effect of LCZ696 in coxsackievirus B3‐induced acute viral myocarditis mice
por: Jing, Xu, et al.
Publicado: (2022)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Clinical Features of Disaster-Related Deaths After the Kumamoto Earthquake 2016　― Comparison With the Great East Japan Earthquake 2011 ―
por: Sueta, Daisuke, et al.
Publicado: (2019)

LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials)
por: Ye, Liwen, et al.
Publicado: (2017)

LCZ696 Ameliorates Isoproterenol-Induced Acute Heart Failure in Rats by Activating the Nrf2 Signaling Pathway
por: Hou, Min, et al.
Publicado: (2022)

The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials
por: Chen, Yan, et al.
Publicado: (2022)

Venous Thromboembolism Due to Oral Contraceptive Intake and Spending Nights in a Vehicle -A Case from the 2016 Kumamoto Earthquakes-
por: Sueta, Daisuke, et al.
Publicado: (2017)

Effects of the Mean Amplitude of Glycemic Excursions and Vascular Endothelial Dysfunction on Cardiovascular Events in Nondiabetic Patients With Coronary Artery Disease
por: Akasaka, Tomonori, et al.
Publicado: (2017)

Determinants of Myocardial Lactate Production During Acetylcholine Provocation Test in Patients With Coronary Spasm
por: Kaikita, Koichi, et al.
Publicado: (2015)

Usefulness of excimer laser atherectomy for balloon uncrossable lesion in chronic total occlusion
por: Sueta, Daisuke, et al.
Publicado: (2015)

LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model
por: Chang, Po-Cheng, et al.
Publicado: (2019)

LCZ696 Attenuated Doxorubicin-Induced Chronic Cardiomyopathy Through the TLR2-MyD88 Complex Formation
por: Ye, Shiju, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2g6cqbmmefrajmehfu5fm98rk7